KR840009063A - 펜에타놀아민 유도체 제조방법 - Google Patents

펜에타놀아민 유도체 제조방법 Download PDF

Info

Publication number
KR840009063A
KR840009063A KR1019840002030A KR840002030A KR840009063A KR 840009063 A KR840009063 A KR 840009063A KR 1019840002030 A KR1019840002030 A KR 1019840002030A KR 840002030 A KR840002030 A KR 840002030A KR 840009063 A KR840009063 A KR 840009063A
Authority
KR
South Korea
Prior art keywords
methyl
formula
compound
group
benzenedimethanol
Prior art date
Application number
KR1019840002030A
Other languages
English (en)
Other versions
KR920004186B1 (ko
Inventor
프레데릭 스키드모어(외 3) 아이안
Original Assignee
배리 안토니 뉴샘
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27449465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR840009063(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB838310477A external-priority patent/GB8310477D0/en
Priority claimed from GB838317087A external-priority patent/GB8317087D0/en
Priority claimed from GB838329568A external-priority patent/GB8329568D0/en
Priority claimed from GB848401889A external-priority patent/GB8401889D0/en
Application filed by 배리 안토니 뉴샘, 글락소 그룹 리미티드 filed Critical 배리 안토니 뉴샘
Publication of KR840009063A publication Critical patent/KR840009063A/ko
Application granted granted Critical
Publication of KR920004186B1 publication Critical patent/KR920004186B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1742—Unsaturated ethers containing halogen containing six-membered aromatic rings with halogen atoms bound to the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1782—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

내용 없음

Description

펜에타놀아민 유도체 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. (1) 다음 일반식(Ⅱ)의 아민을 환원제 존재하에서 다음 일반식(Ⅲ)의 알킬화 시약으로 또는 다음 일반식(Ⅳ)의 화합물로 알킬화시킨 다음에 존재하는 모든 보호기를 제거하거나, 또는
    (2) 다음 일반식(Ⅵ)의 중간체 또는 이들의 보호된 유도체를 환원시킨 다음에 존재하는 모든 보호기를 제거하거나, 또는
    (3) 다음 일반식(Ⅶ)의 화합물과 다음 일반식(Ⅷ)의 아민을 반응시킨 다음에 존재하는 모든 보호기를 제거하거나, 또는
    (4) 다음 일반식(Ⅸ)의 보호된 유도체를 팔보호시키고, 필요에 따라서 이 결과로 생성된 일반식(Ⅰ)의 화합물 또는 이들의 염을 생리적으로 허용되는 이들의 염 또는 용매 화합물로 전환시킴으로써 R1이 수소원자인 일반식(Ⅰ)의 화합물을 제조하는 것을 특징으로 하는 다음 일반식(Ⅰ)의 화합물 또는 생리적으로 허용되는 이들의 염 또는 용매 화합물을 제조하는 방법.
    위의 일반식(Ⅰ)의 화합물에서, m는 2-8의 정수이며, n는 1-7의 정수이되 여기서 m+n의 총계는 4-12이어야 하며, Ar는 비치환 또는 할로겐원자, C1-3알킬 및 알콕시기 중에서 선발된 한개 또 두개의 치환체에 의해서 치환되거나 일반식 -O(CH2)pO-(여기서 p는 1 또는 2임)의 알킬렌디옥시기로 치환된 펜닐기이며, R1및 R|2는 서로 동일하거나 상이하며 각각 수소원자 또는 C1-3알킬기이되 여기서 R1및 R2의 탄소 원자의 총수는 4 미만임.
    위의 일반식(Ⅱ)의 화합물에서, R3,R5및 R6는 각각 수소원자 또는 보호기이며, R4는 수소원자임.
    위의 일반식(Ⅲ)의 화합물에서, m,n,R2및 Ar는 일반식(Ⅰ)의 화합물에서 정의한 바와 같고 L는 이탈기임.
    위의 일반식(Ⅳ)의 화합물에서, R2,m,n 및 Ar는 일반식(Ⅰ)의 화합물에서 의한 바와 같음.
    위의 일반식(Ⅵ)의 화합물에서, n 및 Ar는 일반식(Ⅰ)의 화합물에서 정의한 바와 같고, R5는 수소원자 또는 보호기이며, X,X1,X2,X3및 X|4중의 어느 하나는 환원 가능한 기이되 그 나머지 다른 기들은 X는 CH2OR6이고, X1는 -CH(OH)-, X2는 -CH2NR3이고 X3는 CR1R2(CH)2M-1이며 X는 -(CH2)N-1여기서 R6,R3,R2,R1및 m는 앞서 정의한 바와 같음)임.
    위의 일반식(Ⅶ)의 화합물에서, Z는또는이되, 여기서 R5및 R6는 서로 동일하거나 상이하며, 각각 수소 원자 또는 보호기이고, L는 이탈기임.
    위의 일반식(Ⅷ)의 화합물에서, Y1는 수소원자 또는 촉매 수소화 반응에 의해서 수소원자로 전환 가능한 기이며, R1,R2,m,n및 Ar는 일반식(I)의 화합물에서 정의한 바와 같음.
    위의 일반식(Ⅸ)의 화합물에서, R1,R2,m,n및 Ar는 일반식(I)의 화합물에서 정의한 바와 같고; R3,R5및 R6는 그중 한 가지가 보호기를 제공하는 각각 보호기 또는 수소원자임.
  2. 제1항에 있어서, m가 3이고 n가 6이거나, m이 4이고 n가 3,4또는 5이거나, m이 5이고 이 2,3,4 또는 5이거나 m이 6이고 이 2 또는 3인 제조방법.
  3. 제1항에 있어서, m+n의 총계가 7,8,9 또는 10인 제조방법.
  4. 제7항 내지 3항에 있어서, R1및 R2가 서로 동일하거나 상이하며 각각 수소원자 또는 메틸기인 제조방법.
  5. 제7항 내지 4항에 있어서, Ar가 비치환 펜닐기 또는 염소 및 불소원자, 메톡시기 및 메틸기 중에서 선발된 한개의 치환기로 치환된 펜닐기인 제조방법.
  6. 제1항에 있어서, 생성물이 다음 일반식(Ia)의 화합물 또는 생리적으로 혀용되는 이들의 염 또는 용매화합물인 제조방법.
    위의 일반식(Ia)의 화합물에서, R1및 R2는 제7항의 일반식(I)의 화합물에서 정의한 바와 같고, m는 3-6의 정수이며, n는 2-6의 정수이되 m+n의 총계가 7-70이며, Ar는 폐닐기 또는 메틸 또는 메톡시기 또는 불소 또는 염소원자로 치환된 폐닐기임.
  7. 제6항에 있어서, R1가 수소원자이고 R2가 수소 원자 또는 메틸기인 제조방법.
  8. 제6항에 있어서, R1및 R2가 서로 동일하거나 상이하며 각각 수소원자 또는 메틸기이며, m가 4 또는 5이고, n가 2,3 또는 4 이며, Ar가 페닐기 또는 염소 또는 불소 원자 또는 메톡시기 또는 메틸기로 치환된 페닐기임.
  9. 제1항에 있어서, 생성물이 다음의 화합물 중에서 선발된 화합물 또는 생리적으로 허용되는 이들의 염 또는 용매 화합물인 제조방법.
    4-히드록시-α1-〔〔〔6-(4-페닐부톡시)헥실〕아미노〕메틸〕-7,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔6-(3-페닐프로폭시)헥실〕아미노〕메틸〕-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔6-(2-페닐에톡시)헥실〕아미노〕메틸〕-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔5-(4-페닐에톡시)펜틸〕아미노〕메틸〕-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔1-메틸-6-(2-페닐부톡시)헥실〕아미노〕메틸〕-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔1-메틸-5-(3-페닐프로폭시)펜틸〕아미노〕메틸〕-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔1-메틸-5-(4-페닐부톡시)펜틸〕아미노〕메틸〕-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔1-메틸-6-(2-페닐에톡시)헥실〕아미노〕메틸〕-1,3-벤젠디메타놀,
    α1-〔〔〔1,1-디메틸-6-(2-페닐에톡시)헥실〕아미노〕메틸〕-4-히드록시-1,3-벤젠디메타놀,
    α1-〔〔〔6-2-(4-플루오로페닐)에톡시〕-1메틸헥실)아미노〕메틸〕-4-히드록시-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔6-(3-(4-메톡시페닐)프로폭시〕-1-메틸헥실)아미노〕메틸〕-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔1-메틸-6-(4-페닐부톡시)헥실〕아미노〕메틸〕-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔6-〔2-(4-메틸페닐)에톡시〕헥실)아미노〕메틸〕-1,3-벤젠디메타놀,
    α1-〔〔〔6-〔2-(3-클로로페닐)에톡시)헥실〕아미노〕메틸〕-4-히드록시-1,3-벤젠디메타놀,
    4-히드록시-α1-〔〔〔6-〔2-(4-메톡시페닐)에톡시〕헥실)아미노〕메틸〕-1,3-벤젠디메타놀,
    α1-〔〔〔6-(3-(4-플루오로페닐)프로폭시)헥실〕아미노〕메틸〕-4-히드록시-1,3-벤젠디메타놀,
  10. 제1항 내지 9항에 있어서, 단계(I)에서 아민을 일반식(Ⅲ)의 화합물인 알킬화 시약으로 알킬화하는 반응이 무기 또 유기 염기 또는 산화알킬렌 존재 하, 실온내지 용매의 환류온도 범위에서 수행하는 제조방법.
  11. 제1항 내지 9항에 있어서, 단계(I)에서 아민을 일반식(Ⅳ)의 화합물로 알킬화하는 반응이 수소와 용매로서 알코올 및 (또는) 물 중의 하나를 이용하여 지지하는 금속 촉매 존재 하, 20-100° 및 1-10 기압에서 수행하는 제조방법.
  12. 제1항 내지 9항에 있어서, 단계(I)에서 R3및 R4중의 어느 한기 또는 두기 모두가 수소원자인 경우에 아민을 일반식(Ⅳ)의 화합물인 알킬화하는 반응이 이보란 또는 금속 수소화물 존재하, 용매 존재 하에서 수행하는 제조방법.
  13. 제1항 내지 9항에 있어서, 단계(2)에서 일반식(Ⅵ)의 화합물 중의 CR1R2X5및 (또는) X4가 수소와 촉매를 이용하여-(CH2)n-1(제1항에서 정의한 바와 같음)로 환원되는 -C=C- 또는-CC- 결합 중의 하나를 함유하는 제조방법.
  14. 제1항 내지 9항에 있어서, 단계(3)에서 일반식(Ⅷ)의 화합물에서 Y1으로 나타낸기가 아릴메릴기이며 이 반응이 실온 내지 환류 온도의 범위에서, 경우에 따라서는 염기 존재 하에서 알코올, 할로겐화 탄화수소치환 아미드 또는 에테르 존재하에서 수행되는 제조방법.
  15. 제1항 내지 14항에 있어서, 그 결과로 생성된 일반식(I)의 화합물 또는 이들의 염을 적절한 용매 존재하에서 적당한 산 또는 염기와 반응시켜서 일반식(I)의 화합물의 생리적으로 허용되는 염을 얻는 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840002030A 1983-04-18 1984-04-18 펜에탄올아민 유도체의 제조방법 KR920004186B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB838310477A GB8310477D0 (en) 1983-04-18 1983-04-18 Chemical compounds
GB8310477 1983-04-18
GB838317087A GB8317087D0 (en) 1983-06-23 1983-06-23 Chemical compounds
GB8317087 1983-06-23
GB8329568 1983-11-04
GB838329568A GB8329568D0 (en) 1983-11-04 1983-11-04 Chemical compounds
GB848401889A GB8401889D0 (en) 1984-01-25 1984-01-25 Chemical compounds
GB8401889 1984-01-25

Publications (2)

Publication Number Publication Date
KR840009063A true KR840009063A (ko) 1984-12-24
KR920004186B1 KR920004186B1 (ko) 1992-05-30

Family

ID=27449465

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840002030A KR920004186B1 (ko) 1983-04-18 1984-04-18 펜에탄올아민 유도체의 제조방법

Country Status (37)

Country Link
US (5) US4992474A (ko)
JP (2) JPS63264443A (ko)
KR (1) KR920004186B1 (ko)
AR (3) AR244199A1 (ko)
AT (1) AT390611B (ko)
AU (1) AU573212B2 (ko)
BE (1) BE899448A (ko)
BG (1) BG61490B2 (ko)
CA (2) CA1335999C (ko)
CH (2) CH661497A5 (ko)
CY (1) CY1482A (ko)
CZ (1) CZ285602B6 (ko)
DE (4) DE3448452C2 (ko)
DK (2) DK167493B1 (ko)
ES (2) ES8505641A1 (ko)
FI (1) FI85011C (ko)
FR (1) FR2545482B1 (ko)
GB (2) GB2140800B (ko)
GR (1) GR79925B (ko)
HK (1) HK36889A (ko)
HU (1) HU200160B (ko)
IE (1) IE57237B1 (ko)
IL (1) IL71569A (ko)
IT (1) IT1199112B (ko)
KE (1) KE3864A (ko)
LU (2) LU88265I2 (ko)
MX (1) MX9203226A (ko)
MY (1) MY102087A (ko)
NL (2) NL188406C (ko)
NO (2) NO159016C (ko)
NZ (2) NZ207885A (ko)
PH (1) PH21574A (ko)
PT (1) PT78443B (ko)
SE (1) SE462594B (ko)
SG (1) SG12289G (ko)
SK (1) SK278120B6 (ko)
ZW (1) ZW6584A1 (ko)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
NZ211822A (en) * 1984-04-17 1988-11-29 Glaxo Group Ltd Phenethanolamine derivatives and pharmaceutical compositions
US4943591A (en) * 1984-10-17 1990-07-24 Glaxo Group Limited Dichloroaniline derivatives
GB8525321D0 (en) * 1985-10-15 1985-11-20 Glaxo Group Ltd Chemical compounds
EP0223410A3 (en) * 1985-10-16 1987-11-19 Glaxo Group Limited Ethanolamine derivatives
GB8525483D0 (en) * 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
GB8525484D0 (en) * 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
EP0220054A3 (en) * 1985-10-16 1987-12-02 Glaxo Group Limited Ethanolamine derivatives
JPS63290852A (ja) * 1987-02-10 1988-11-28 グラクソ、グループ、リミテッド 化合物
EP0286242A3 (en) * 1987-03-12 1989-08-09 Glaxo Group Limited Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them
GB8718938D0 (en) * 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
GB8718940D0 (en) * 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
NZ226934A (en) * 1987-11-13 1991-01-29 Glaxo Group Ltd Phenethanolamine derivatives and pharmaceutical compositions
EP0322164B1 (en) * 1987-12-18 1993-09-22 Glaxo Group Limited Ethanolamine derivatives
ZA889405B (en) * 1987-12-18 1989-12-27 Glaxo Group Ltd Ethanolamine derivatives
GB8909273D0 (en) * 1989-04-24 1989-06-07 Glaxo Group Ltd Chemical compounds
GB2230775A (en) * 1989-04-24 1990-10-31 Glaxo Group Ltd Phenethanolamine compounds
EP0416925A3 (en) * 1989-09-07 1991-09-25 Glaxo Group Limited Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
US5290815A (en) * 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
FR2651678B1 (fr) * 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
TW209832B (ko) * 1989-10-10 1993-07-21 Glaxo Group Ltd
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
YU48707B (sh) 1990-03-02 1999-07-28 Glaxo Group Limited Aparat za inhaliranje - inhalator
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
GB9026005D0 (en) * 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
AP323A (en) * 1992-05-08 1994-03-07 Glaxo Group Ltd Drug material suitable for micronisation.
GB9215274D0 (en) * 1992-07-17 1992-09-02 Scras Derivatives of(phenylethyl-beta-ol)amine
ES2065269B1 (es) * 1993-05-11 1995-10-01 S A L V A T Lab Sa 6-(4-(fenilbutoxi) hexilaminometil-4-hidroxi-a1,a3-bencenodimetanol. procedimiento para la obtencion del mismo y nuevos intermedios utilizados en su preparacion.
HU221500B (en) * 1993-12-10 2002-10-28 Novartis Ag 3-[6-(4-phenylbutoxy)hexyl]-5-(4-hydroxy-3-hydroxymethylphenyl)-oxazolidine, use thereof, process for preparing it and pharmaceutical compositions containing the same
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
BR9604976A (pt) * 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador de dose medida sistema inalador de dose medida e uso do mesmo
NZ306281A (en) * 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler with part or all internal surfaces coated with fluorocarbon polymers for dispensing beclomethasone dipropionate
ES2276736T3 (es) 1995-04-14 2007-07-01 Smithkline Beecham Corporation Inhalador medidor de dosis para propionato de flucticasona.
ATE250439T1 (de) 1995-04-14 2003-10-15 Smithkline Beecham Corp Dosierinhalator für salmeterol
EP0947498B1 (en) 1996-12-02 2004-09-15 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
EA003741B1 (ru) * 1998-06-01 2003-08-28 Энтони Дж. Вербискар Местное трансдермальное лечение
ES2142771B1 (es) * 1998-09-28 2001-01-01 Vita Invest Sa Nuevos derivados de la 6-(4-fenil-butoxi) hexilamina y procedimiento para la obtencion de salmeterol.
EP1169019B1 (en) 1999-04-14 2003-02-26 Glaxo Group Limited Pharmaceutical aerosol formulation
CA2715683A1 (en) * 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0014546D0 (en) * 2000-06-14 2000-08-09 Glaxo Group Ltd A novel process
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
OA12394A (en) * 2000-08-05 2004-07-09 Glaxo Group Ltd 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent.
US20030207057A1 (en) 2000-09-18 2003-11-06 Britto Ignatius Loy Metered dose inhaler can coated two or more times with fluorocarbon polymers
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP2039700A2 (en) * 2001-04-30 2009-03-25 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
WO2002098404A1 (en) * 2001-06-01 2002-12-12 Tendskin Company Topical compositions for veterinary uses
PT1425001E (pt) * 2001-09-14 2009-02-18 Glaxo Group Ltd Derivados de fenetanolamina para o tratamento de doenças respiratórias
US6680345B2 (en) 2001-09-14 2004-01-20 Boehringer Ingelheim Pharma Kg Salicylic acid salts of salmeterol
EP1429751A1 (de) * 2001-09-14 2004-06-23 Boehringer Ingelheim Pharma GmbH & Co.KG Salicylsäuresalze, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6756508B2 (en) 2002-03-04 2004-06-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Cinnamic acid salts, processes for their preparation, and their use as medicaments
CA2477714C (en) * 2002-03-04 2011-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
DE10209583B4 (de) * 2002-03-05 2006-01-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von 4-(6-Bromhexyloxy)-butylbenzol
US6835857B2 (en) 2002-03-05 2004-12-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene
US7378438B2 (en) * 2002-04-19 2008-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US7271197B2 (en) 2002-04-25 2007-09-18 Glaxo Group Limited Phenethanolamine derivatives
EP1507754A1 (en) 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
DE10249576B3 (de) * 2002-10-24 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (R)-Salbutamol
GB0225030D0 (en) * 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
AU2003286143A1 (en) 2002-10-28 2004-05-13 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225535D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004060260A2 (en) * 2002-12-18 2004-07-22 Glaxo Group Limited Drug delivery system with vented mouthpiece
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) * 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7358244B2 (en) * 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
ES2449718T3 (es) 2003-08-11 2014-03-20 Glaxo Group Limited Inhalador de dosis farmacéutica medida y procedimiento relacionados con el mismo
GB0319826D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Process
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
WO2005053647A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Medical product containing tiotropium
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
GB0329182D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
KR20060135873A (ko) * 2004-03-12 2006-12-29 씨아이피엘에이 엘티디. 살메테롤 흡입 제제
US20080039495A1 (en) * 2004-06-03 2008-02-14 Linsell Martin S Diamine Beta2 Adrenergic Receptor Agonists
EP1778638A1 (en) * 2004-07-21 2007-05-02 Theravance, Inc. Diaryl ether beta2 adrenergic receptor agonists
JP2008512470A (ja) * 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
ES2317306T3 (es) 2004-10-12 2009-04-16 Generics (Uk) Limited Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol.
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
DE102005033732B4 (de) * 2005-05-27 2014-02-13 Grünenthal GmbH Trennung stereoisomerer N,N-Dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkane
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
PL1937626T3 (pl) * 2005-10-17 2016-08-31 Generics Uk Ltd Sposób i związki do otrzymywania salmeterolu
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
WO2007079466A2 (en) * 2006-01-04 2007-07-12 Nano Mist International, Llc Air driven delivery system for sprayable media
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2009529539A (ja) * 2006-03-07 2009-08-20 エンダセア， インコーポレイテッド 呼吸器障害を治療するための方法および組成物
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
MY155277A (en) * 2006-08-22 2015-09-30 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
US20110021473A1 (en) * 2006-09-22 2011-01-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
US20080319086A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched salmeterol
US20090048155A1 (en) 2007-08-15 2009-02-19 Endacea, Inc. Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2222676A4 (en) 2007-12-21 2011-10-26 Endacea Inc A1-adenosine receptor antagonistic
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
EP2662027B1 (en) 2008-05-09 2017-09-27 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
EP2127641A1 (en) 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI695723B (zh) 2009-05-29 2020-06-11 美商沛爾醫療股份有限公司 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
CN104042322B (zh) * 2009-10-27 2017-06-06 赫莱拉公司 具有可冷却的能量发射组件的递送装置
EP4111995A1 (en) 2009-11-11 2023-01-04 Nuvaira, Inc. Device for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
TR201000685A2 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
CN103119030A (zh) 2010-07-30 2013-05-22 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
WO2012032546A2 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
KR20130140688A (ko) 2010-09-24 2013-12-24 랜박시 래보러터리스 리미티드 기질 메탈로프로테나제 저해제
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN103864629A (zh) * 2012-12-13 2014-06-18 天津金耀集团有限公司 昔萘酸沙美特罗的精制方法
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
US20160129207A1 (en) 2013-06-17 2016-05-12 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation composition filling method
CN104744271B (zh) * 2013-12-26 2016-08-31 成都伊诺达博医药科技有限公司 一种合成维兰特罗的新工艺
US9447067B2 (en) 2014-10-03 2016-09-20 Amphastar Pahmaceuticals, Inc. Method of preparing intermediate of salmeterol
WO2016142582A1 (en) 2015-03-11 2016-09-15 Fermion Oy Process for the preparation of crystalline salmeterol and its xinafoate salt
KR20240042438A (ko) 2021-07-09 2024-04-02 아스트라제네카 파마수티컬스 엘피 에어로졸 약물 전달을 위한 조성물, 방법 및 시스템
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
WO2024006226A1 (en) * 2022-06-26 2024-01-04 Alexander Shulgin Research Institute, Inc. N-substituted phenylalkylamines and their use as therapeutic agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1451357A (fr) * 1965-07-01 1966-01-07 Soc Ind Fab Antibiotiques Sifa Nouveaux alcools dérivés de l'éthano-9, 10 dihydro-9, 10 anthracene et procédé de préparation
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
GB1321701A (en) * 1969-10-01 1973-06-27 Continental Pharma Amino-alcohols their salts and process for prepairing the same
US4137328A (en) * 1970-07-18 1979-01-30 Pfizer Inc. Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants
AT310146B (de) * 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
US3879442A (en) * 1972-07-27 1975-04-22 Warner Lambert Co 5-hydroxy-{60 (substituted aminomethyl)-mu-xylene-{60 ,{60 -diols
GB1511159A (en) * 1975-07-10 1978-05-17 Leo A Amines preparation
GB1529972A (en) * 1975-07-29 1978-10-25 Allen & Hanburys Ltd Basic alcohols
US4160036A (en) * 1975-07-29 1979-07-03 Allen & Hanburys Limited 4-Hydroxy-1,3-benzenedimethanol derivatives
US4154761A (en) * 1976-02-09 1979-05-15 Allen & Hanburys Limited Pharmacologically active compounds
JPS52113934A (en) * 1976-03-19 1977-09-24 Eisai Co Ltd Phenethylamine derivatives and bronchodilator containing the same
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them
DE2833140A1 (de) * 1978-07-28 1980-02-07 Boehringer Sohn Ingelheim Neue n-substituierte heterocyclen
US4160367A (en) * 1978-09-11 1979-07-10 General Motors Corporation Dual container additive dispenser for appliance
EP0021636B1 (en) * 1979-06-16 1982-12-01 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
FR2460919A1 (fr) * 1979-07-11 1981-01-30 Prod Synthese Ste Indle Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique
US4288456A (en) * 1980-09-19 1981-09-08 E. R. Squibb & Sons, Inc. Compositions containing 1-aryl-5-(2-propenylamino)-1-penten-3-ones and method for treating inflammatory conditions
US4379166A (en) * 1981-08-03 1983-04-05 Schering Corporation Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols
EP0103830A3 (de) * 1982-09-22 1985-07-31 Bayer Ag Wachstumsfördernde Phenylethylamin-Derivate
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
NZ211822A (en) * 1984-04-17 1988-11-29 Glaxo Group Ltd Phenethanolamine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
DK201784A (da) 1984-10-19
KR920004186B1 (ko) 1992-05-30
JPS63264443A (ja) 1988-11-01
CA1336004C (en) 1995-06-20
PH21574A (en) 1987-12-11
NO159016C (no) 1988-11-23
NL930066I1 (nl) 1993-09-01
NO159016B (no) 1988-08-15
FR2545482A1 (fr) 1984-11-09
DE19575029I2 (de) 2002-11-07
DK158092A (da) 1992-12-30
SG12289G (en) 1989-07-07
NL188406B (nl) 1992-01-16
NL930066I2 (nl) 1993-10-01
ES539625A0 (es) 1986-07-16
CH661497A5 (fr) 1987-07-31
IE840965L (en) 1984-10-18
FI85011C (fi) 1992-02-25
SE462594B (sv) 1990-07-23
JPH0687800A (ja) 1994-03-29
US5243076A (en) 1993-09-07
PT78443B (en) 1986-08-28
US5225445A (en) 1993-07-06
NL188406C (nl) 1992-06-16
US4992474A (en) 1991-02-12
IT8448064A0 (it) 1984-04-18
CA1335999C (en) 1995-06-20
ATA129184A (de) 1989-11-15
DE3414752A1 (de) 1984-10-18
GB2140800B (en) 1987-09-23
NL8401258A (nl) 1984-11-16
GB2140800A (en) 1984-12-05
JPH0569817B2 (ko) 1993-10-01
AR244199A1 (es) 1993-10-29
HK36889A (en) 1989-05-12
CH667084A5 (fr) 1988-09-15
AU2706484A (en) 1984-10-25
DK167493B1 (da) 1993-11-08
SE8402188L (sv) 1984-10-19
ZW6584A1 (en) 1985-04-17
BG61490B2 (bg) 1997-09-30
DE3448452C2 (de) 1994-01-05
NO1994017I1 (no) 1994-09-22
CZ285602B6 (cs) 1999-09-15
JPH0729997B2 (ja) 1995-04-05
GB8410124D0 (en) 1984-05-31
ES531722A0 (es) 1985-06-01
IE57237B1 (en) 1992-06-17
DE3448338C2 (ko) 1993-05-19
SK402891A3 (en) 1995-07-11
MY102087A (en) 1992-03-31
HU200160B (en) 1990-04-28
FR2545482B1 (fr) 1988-06-17
FI85011B (fi) 1991-11-15
DK201784D0 (da) 1984-04-18
AR245687A1 (es) 1994-02-28
FI841548A0 (fi) 1984-04-18
AU573212B2 (en) 1988-06-02
GB2176476B (en) 1987-12-31
IT1199112B (it) 1988-12-30
IL71569A0 (en) 1984-07-31
FI841548A (fi) 1984-10-19
NO841568L (no) 1984-10-19
US5091422A (en) 1992-02-25
GR79925B (ko) 1984-10-31
ES8505641A1 (es) 1985-06-01
GB2176476A (en) 1986-12-31
CY1482A (en) 1989-12-08
DK158092D0 (da) 1992-12-30
NZ221999A (en) 1988-11-29
LU85329A1 (fr) 1985-06-04
SK278120B6 (en) 1996-02-07
DK175083B1 (da) 2004-05-24
MX9203226A (es) 1992-07-01
SE8402188D0 (sv) 1984-04-18
DE3414752C2 (ko) 1993-03-25
CZ402891A3 (en) 1993-05-12
PT78443A (pt) 1984-05-01
US5126375A (en) 1992-06-30
KE3864A (en) 1989-05-19
NZ207885A (en) 1988-11-29
IL71569A (en) 1987-10-30
LU88265I2 (ko) 1994-02-03
BE899448A (fr) 1984-10-18
AR247721A1 (es) 1995-03-31
GB8612357D0 (en) 1986-06-25
AT390611B (de) 1990-06-11
ES8609209A1 (es) 1986-07-16

Similar Documents

Publication Publication Date Title
KR840009063A (ko) 펜에타놀아민 유도체 제조방법
KR850004459A (ko) 인돌유도체의 제조방법
KR830006156A (ko) 치환된 할로겐부위를 갖는 플루오로카본 에테르의 제조방법
KR830010077A (ko) 벤자제핀 유도체의 제조방법
KR850003890A (ko) 1H-이미다조[4,5c]-퀴놀린-4-아민의 제조방법
KR850001229A (ko) 4'-탈메틸-4-에피포도필로톡신 유도체의 제조방법
KR840001145A (ko) 피리다진의 아미노 화합물의 제조방법
KR950701902A (ko) 리그난계 화합물의 제조방법(process for producing lignan compound)
KR860004071A (ko) 유기고분자 화합물 안정제 및 제조방법
KR860008200A (ko) 신규한 4'-탈메틸-4-에피포도필로톡신 유도체의 제조방법
KR830007505A (ko) 페닐알킬아민의 제조방법
KR870007196A (ko) 화학적 제조방법
KR890011904A (ko) 안드로스타-1,4, -디엔-3,17-디온의 6-메틸렌 유도체 합성방법
KR850005845A (ko) 7-아미노-3-치환된-메틸-3-세펨-4-카복실산 및 그의 저급 알킬실릴 유도체의 제조방법
KR840001555A (ko) 치환된 2-페닐-2-(피리딜욕시)-에틸아민과 그의 등 배전자화합물 및 그들의 산부가염을 제조하는 방법
KR880003913A (ko) 나프틸 유도체, 그를 함유하는 약제학적 조성물 및 그의 제조방법
KR890012931A (ko) 4-데메톡시다우노루비신의 아글리콘인 4-데메톡시다우노마이시논의 제조방법
KR870007881A (ko) 신규 알킬렌디아민 유도체의 제조방법
KR830005260A (ko) 2'-디옥시-3',5'-디-0-알킬카르보닐-5-플루오르우리딘 유도체 및 그의 제조방법과 이를 함유하는 항종양제
KR830004263A (ko) 신규 소염제 및 면역 조절제인 피리딘과 피리미딘의 제조방법
KR840005723A (ko) 티아졸유도체의 제조방법
KR860008135A (ko) 아미노케톤 유도체의 제조방법
KR890002036A (ko) 아졸유도체, 그의 제조방법, 및 그를 함유한 식물질병 억제용 제제
KR830007601A (ko) 티아졸린 유도체의 제조방법
KR830007647A (ko) 벤조헤테로사이클릭 화합물의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030410

Year of fee payment: 12

EXPY Expiration of term